Antibodies directed against merozoite surface protein-6 are induced by natural exposure to Plasmodium falciparum in a low transmission environment

Parasite Immunology

Volumn 33, Issue 7, 2011, Pages 401-410

  Jordan, S J ^a,b   Oliveira, A L ^a   Neal, A T ^a,c   Hernandez, J N ^d   Branch, O H ^e   Rayner, J C ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSIDAD NACIONAL DE LA AMAZONÍA PERUANA   (Peru)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

Cross reactivity; Immunity; Malaria; Merozoite; PfMSP6; Plasmodium falciparum; Vaccine

Indexed keywords

ANTIBODY; ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; MEMBRANE PROTEIN; MEROZOITE SURFACE PROTEIN 3; MEROZOITE SURFACE PROTEIN 6; UNCLASSIFIED DRUG;

ALLELE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CORRELATION ANALYSIS; ENVIRONMENTAL FACTOR; GENOTYPE; HUMAN; IMMUNE RESPONSE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; PERU; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SEROEPIDEMIOLOGIC STUDIES;

PLASMODIUM FALCIPARUM;

EID: 79959226732     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2011.01299.x     Document Type: Article

References (37)

1. Carlton JM, Adams JH, Silva JC, et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 2008; 455: 757-763.
2. Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002; 419: 498-511.
3. Pain A, Bohme U, Berry AE, et al. The genome of the simian and human malaria parasite Plasmodium knowlesi. Nature 2008; 455: 799-803.
4. Coppel RL. Vaccinating with the genome: a Sisyphean task? Trends Parasitol 2009; 25: 205-212.
5. Takala SL & Plowe CV. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol 2009; 31: 560-573.
6. Ochola LI, Tetteh KK, Stewart LB, Riitho V, Marsh K & Conway DJ. Allele frequency-based and polymorphism-versus-divergence indices of balancing selection in a new filtered set of polymorphic genes in Plasmodium falciparum. Mol Biol Evol 2010; 27: 2344-2351.
7. Trucco C, Fernandez-Reyes D, Howell S, et al. The merozoite surface protein 6 gene codes for a 36kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol Biochem Parasitol 2001; 112: 91-101.
8. Kauth CW, Woehlbier U, Kern M, et al. Interactions between merozoite surface proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum. J Biol Chem 2006; 281: 31517-31527.
9. Koussis K, Withers-Martinez C, Yeoh S, et al. A multifunctional serine protease primes the malaria parasite for red blood cell invasion. EMBO J 2009; 28: 725-735.
10. Pearce JA, Triglia T, Hodder AN, Jackson DC, Cowman AF & Anders RF. Plasmodium falciparum merozoite surface protein 6 is a dimorphic antigen. Infect Immun 2004; 72: 2321-2328.
11. Roy SW, Weedall GD, da Silva RL, Polley SD & Ferreira MU. Sequence diversity and evolutionary dynamics of the dimorphic antigen merozoite surface protein-6 and other Msp genes of Plasmodium falciparum. Gene 2009; 443: 12-21.
12. Neal AT, Jordan SJ, Oliveira AL, Hernandez JN, Branch OH & Rayner JC. Limited variation in vaccine candidate Plasmodium falciparum Merozoite Surface Protein-6 over multiple transmission seasons. Malar J 2010; 9: 138.
13. Singh S, Soe S, Weisman S, Barnwell JW, Perignon JL & Druilhe P. A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum. PLoS One 2009; 4: e5410.
14. Oeuvray C, Bouharoun-Tayoun H, Grass-Masse H, et al. A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Mem Inst Oswaldo Cruz 1994; 89(Suppl 2): 77-80.
15. Singh S, Soe S, Mejia JP, et al. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J Infect Dis 2004; 190: 1010-1018.
16. Osier FH, Polley SD, Mwangi T, Lowe B, Conway DJ & Marsh K. Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3. Parasite Immunol 2007; 29: 387-394.
17. Polley SD, Tetteh KK, Lloyd JM, et al. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 2007; 195: 279-287.
18. Roussilhon C, Oeuvray C, Muller-Graf C, et al. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med 2007; 4: e320.
19. Hisaeda H, Saul A, Reece JJ, et al. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J Infect Dis 2002; 185: 657-664.
20. Druilhe P, Spertini F, Soesoe D, et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2005; 2: e344.
21. Sirima SB, Nebie I, Ouedraogo A, et al. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 2007; 25: 2723-2732.
22. Lusingu JP, Gesase S, Msham S, et al. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24months. Malar J 2009; 8: 163.
23. Daher LJ, Demanga CG, Prieur E, Perignon JL, Bouharoun-Tayoun H & Druilhe P. Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of immunogenicity studies in models. Infect Immun 2010; 78: 477-485.
24. Demanga CG, Daher LJ, Prieur E, et al. Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans. Infect Immun 2010; 78: 486-494.
25. Singh S, Soe S, Roussilhon C, Corradin G & Druilhe P. Plasmodium falciparum merozoite surface protein 6 displays multiple targets for naturally occurring antibodies that mediate monocyte-dependent parasite killing. Infect Immun 2005; 73: 1235-1238.
26. Wang L, Crouch L, Richie TL, Nhan DH & Coppel RL. Naturally acquired antibody responses to the components of the Plasmodium falciparum merozoite surface protein 1 complex. Parasite Immunol 2003; 25: 403-412.
27. Branch O, Casapia WM, Gamboa DV, et al. Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community. Malar J 2005; 4: 27.
28. Jordan SJ, Oliveira AL, Hernandez JN, et al. Malaria immunoepidemiology in low transmission: correlation of infecting genotype and immune response to domains of Plasmodium falciparum merozoite surface protein-3. Infect Immun 2011; 79: 2070-2078.
29. Burgess BR, Schuck P & Garboczi DN. Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. J Biol Chem 2005; 280: 37236-37245.
30. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S & Druilhe P. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 2000; 68: 2617-2620.
31. Stanisic DI, Richards JS, McCallum FJ, et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 2009; 77: 1165-1174.
32. Taylor RR, Allen SJ, Greenwood BM & Riley EM. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 1998; 58: 406-413.
33. Ogutu BR, Apollo OJ, McKinney D, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 2009; 4: e4708.
34. Sagara I, Dicko A, Ellis RD, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009; 27: 3090-3098.
35. Polley SD, Conway DJ, Cavanagh DR, et al. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 2006; 24: 4233-4246.
36. Greenwood B & Targett G. Do we still need a malaria vaccine? Parasite Immunol 2009; 31: 582-586.
37. Holder AA. Malaria vaccines: where next? PLoS Pathog 2009; 5: e1000638.